Coulter & Idec

Sorting out antibody competition

Coulter Pharmaceutical Inc. isn't alone in developing an anti-CD20 antibody for lymphoma. Idec Pharmaceuticals Corp. (IDPH) is developing its own antibody in several configurations: as a "cold" antibody treatment; in combination with CHOP chemotherapy, and as a "hot" antibody conjugated with the radioisotope yttrium.

In addition to their competition in the clinic, the companies differ in their assessment of the